Pierre Kemula
Net worth: - $ as of 31/05/2026
Net worth: - $ as of 31/05/2026
Mr. Pierre Kemula is a Chief Financial Officer at CureVac NV and a Chief Financial Officer at CureVac AG. Mr. Kemula was previously employed as a Chief Financial Officer by Pixium Vision SA and a VP-Treasury, Financial Markets & Corporate Finance by Ipsen SA. He received his undergraduate degree from London School of Economics & Political Science.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| AGOMAB THERAPEUTICS NV | Director of Finance/CFO | 01/11/2024 |
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Director of Finance/CFO | 01/01/2016 |
| Companies | Position | End |
|---|---|---|
| CUREVAC | Director of Finance/CFO | 31/10/2024 |
| PIXIUM VISION | Director of Finance/CFO | 16/02/2017 |
| IPSEN | Public Communications Contact | 01/01/2014 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Ipsen SA
Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
London School of Economics & Political Science
London School of Economics & Political Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pixium Vision SA
Pixium Vision SA Medical SpecialtiesHealth Technology Operates as a bioelectronics company that develops bionic vision systems | Health Technology |
AgomAb Therapeutics NV
AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
CureVac NV
CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions